ClinicalTrials.gg
TerminatedNCT02653417Updated Mar 13, 2019Results posted

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

A Phase 2 interventional study of RAD1901 and Placebo in Vasomotor Symptoms and Hot Flashes, sponsored by Radius Pharmaceuticals, Inc.. Terminated at 1 site in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-13.

Sponsored by Radius Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor's Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Enrollment
57th of 180
139 · median 84
Started
2015
with 4 others
Phase 2
41 of 193
6 open now
Registered
121st of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 57th largest by enrollment of the 180 interventional ones that give a count, is one of 5 that started in 2015, is one of 41 in phase 2, and was the 121st registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.

Read the detailed description

This was a Phase 2b outpatient, prospective, multicenter, double-blind, randomized, placebo-controlled study to determine whether elacestrant reduces the frequency and severity of vasomotor symptoms (VMS; "hot flashes") in postmenopausal women with moderate to severe hot flashes. Postmenopausal women who met study criteria were followed for 12 weeks on double-blind study medication and two weeks off study medication.

Treatment was randomized 1:1:1:1 to ensure that an approximately equal number of patients were exposed to each of three RAD1901 (elacestrant) doses (5, 10 and 20 mg/day) or placebo. The total period of placebo exposure was 14 weeks.

Enrolling approximately 300 patients was expected to provide power for testing superiority of the primary efficacy endpoint outcomes.

03

Conditions studied

  • Vasomotor Symptoms
  • Hot Flashes

Browse trials for

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To have participated in this study, a subject MUST:

  1. be a woman between 40 and 65 years of age, inclusive
  2. be seeking relief or treatment for moderate to severe VMS
  3. be willing to discontinue and abstain from the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; progestin implants; injectable estrogen; topical progesterone cream, selective estrogen receptor modulators and intrauterine devices (IUDs)
  4. have no abnormalities on pelvic exam except for vulvovaginal atrophy (VVA)
  5. have a normal or clinically insignificant transvaginal ultrasound (TVU) with an endometrial thickness \<4 mm at screening
  6. have a normal endometrial subsequent to the TVU without clinically relevant results
  7. have a normal screening Papanicolaou (Pap) smear
  8. have a mammogram within 9 months prior to randomization. Subjects must have had a Breast Imaging Reporting and Data System (BI-RADS) mammography result of 1 or 2 to enroll.

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following characteristics were not be eligible to participate in the study:

  1. have a history of invasive breast cancer or ductal carcinoma in situ, melanoma or any gynecologic cancer.
  2. using any of the following:

    • oral estrogen-, progestin-, androgen-, or selective estrogen receptor modulator (SERM) containing drug products within 8 weeks before screening (visit 1)
    • transdermal hormone products within 4 weeks before screening (visit 1)
    • vaginal hormone products (rings, creams, gels) within 4 weeks before screening (visit 1)
    • progestin implants/injectables, IUDs or estrogen pellets/injectables within 6 months before screening (visit 1)
    • anabolic steroids
  3. have been treated with a gonadotropin-releasing hormone (GnRH) agonist within the last year
  4. have been treated with anti-estrogens or aromatase inhibitors within 2 months prior to study entry
  5. have been concurrently treated and will abstain from gabapentin and paroxetine or serotonin and norepinephrine reuptake inhibitors (SNRIs) for VMS or other indications for 3 months during the trial and have not taken within 4 weeks prior to screening
  6. have unexplained vaginal bleeding within the 3 months prior to study entry
  7. have an endometrial at baseline with a diagnosis by a gynecologic pathologist of proliferative, hyperplasia, polyp or cancer
  8. have unresolved cervical cytological smear report of atypical glandular or squamous cells of undetermined significance. Cervical cytologic smear report of ASCUS, low grade squamous intraepithelial lesion or greater, or any reported dysplasia
  9. have unresolved findings suspicious for on the breast examination
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Regimen 1

    RAD1901 5 mg/day

    Drug: RAD1901

  • Experimental
    Regimen 2

    RAD1901 10 mg/day

    Drug: RAD1901

  • Experimental
    Regimen 3

    RAD1901 20 mg/day

    Drug: RAD1901

  • Placebo comparator
    Regimen 4

    Placebo

    Other: Placebo

Interventions

  • RAD1901

    Also known as: Elacestrant

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes

    Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency. Severity of hot flashes was self-assessed and reported as follows: * Mild: sensation of heat without sweating * Moderate: sensation of heat with sweating, able to continue activity * Severe: sensation of heat with sweating, causing cessation of activity.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes

    Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.

    Time frame: Baseline and 4 weeks

  2. Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes

    Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity. Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is, Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes. The measure is a weighted average of the frequencies of Hot Flashes.

    Time frame: Baseline, 4 weeks, and 12 weeks

  3. Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes

    Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.

    Time frame: Baseline, 4 weeks, and 12 weeks

07

Results

Posted Mar 13, 2019

Participant flow

Participant flow — Overall Study
MilestoneRegimen 1Regimen 2Regimen 3Regimen 4
Started38342938
Completed37322633
Not completed1235

Outcome measures

PrimaryChange From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes

Change from baseline to week 12 in the average number of moderate and severe hot flashes per day, where change is calculated as week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency. Severity of hot flashes was self-assessed and reported as follows: * Mild: sensation of heat without sweating * Moderate: sensation of heat with sweating, able to continue activity * Severe: sensation of heat with sweating, causing cessation of activity.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · moderate to severe hot flashes per day
Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes
moderate to severe hot flashes per dayRegimen 1Regimen 2Regimen 3Regimen 4
Change From Baseline to Week 12 in the Frequency of Moderate to Severe Hot Flashes-3.48 ± 0.793-3.74 ± 0.867-4.12 ± 0.944-3.66 ± 0.808
Statistical analysis
  • Regimen 1 vs Regimen 4 · Mean difference (final values): -0.18
  • Regimen 2 vs Regimen 4 · Mean difference (final values): 0.08
  • Regimen 3 vs Regimen 4 · Mean difference (final values): 0.46
SecondaryChange From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes

Change from baseline to week 4 in the average number of moderate and severe hot flashes per day, where change is calculated as week 4 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · moderate to severe hot flashes per day
Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes
moderate to severe hot flashes per dayRegimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 Placebo
Change From Baseline to Week 4 in the Frequency of Moderate to Severe Hot Flashes-1.15 ± 3.644-2.22 ± 4.872-2.70 ± 3.764-3 ± 4.075
SecondaryChange From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes

Change from baseline to week 4 and week 12 in the average daily severity of hot flashes, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash severity. Subjects recorded the number of hot flashes per day using an electronic diary. Daily severity score for hot flashes for each subject was calculated as the sum of the number of mild hot flashes, plus 2 times the number of moderate hot flashes, plus 3 times the number of severe hot flashes, divided by the total number of mild, moderate, and severe hot flashes. That is, Daily Severity Score = (Fmild + 2•Fmod + 3•Fsev)/(Fmild + Fmod + Fsev) where Fmild= frequency of mild hot flashes, Fmod = frequency of moderate hot flashes, Fsev = frequency of severe hot flashes. The measure is a weighted average of the frequencies of Hot Flashes.

Time frame:
Baseline, 4 weeks, and 12 weeks
Reported as:
Mean · hot flash severity score per day
Change From Baseline to Week 4 and Week 12 in the Severity of Hot Flashes
hot flash severity score per dayRegimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 Placebo
Week 4 change from baseline in severity-0.04 ± 0.25-0.07 ± 0.26-0.13 ± 0.273-0.00 ± 0.280
Week 12 change from baseline in severity-0.09 ± 0.337-0.08 ± 0.373-0.13 ± 0.313-0.01 ± 0.409
SecondaryChange From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes

Change from baseline to week 4 and week 12 in the average number of all hot flashes (mild, moderate, and severe) by eDiary, where change is calculated as week 4 or week 12 minus baseline so that negative values indicate a reduction (improvement) of hot flash frequency.

Time frame:
Baseline, 4 weeks, and 12 weeks
Reported as:
Mean · hot flashes per day
Change From Baseline to Week 4 and Week 12 in the Frequency of All Hot Flashes
hot flashes per dayRegimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 Placebo
Week 4 change from baseline-0.99 ± 3.803-2.23 ± 4.792-2.29 ± 3.754-3.27 ± 4.107
Week 12 change from baseline-3.47 ± 5.076-2.40 ± 3.560-3.91 ± 5.263-3.74 ± 4.228

Adverse events

Collected over Up to 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen 1 RAD1901 5 mg0/38 (0%)0/38 (0%)11/38 (28.9%)
Regimen 2 RAD1901 10 mg0/34 (0%)0/34 (0%)3/34 (8.8%)
Regimen 3 RAD1901 20 mg0/29 (0%)0/29 (0%)7/29 (24.1%)
Regimen 4 Placebo0/38 (0%)0/38 (0%)13/38 (34.2%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRegimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 Placebo
NauseaGastrointestinal disorders1/380/340/294/38
Vaginal haemorrhageReproductive system and breast disorders2/381/341/294/38
DyspepsiaGastrointestinal disorders0/381/342/291/38
Upper respiratory tract infectionInfections and infestations1/380/342/292/38
DiarrhoeaGastrointestinal disorders1/380/341/292/38
Abdominal PainGastrointestinal disorders0/381/340/292/38
SinusitisInfections and infestations0/380/341/292/38
HeadacheNervous system disorders2/381/341/292/38
Back painMusculoskeletal and connective tissue disorders2/381/340/290/38
ArthralgiaMusculoskeletal and connective tissue disorders2/380/340/290/38

Baseline characteristics

mITT population

Age, Continuous
Age, Continuous(years)Regimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 PlaceboTotal
Mean56.6 ± 4.8355.4 ± 5.0854.1 ± 4.0753.9 ± 5.0955.1 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)Regimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 PlaceboTotal
Female38342838138
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 PlaceboTotal
Hispanic or Latino887629
Not Hispanic or Latino30262132109
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 PlaceboTotal
American Indian or Alaska Native10113
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American61261034
White30222127100
More than one race00000
Unknown or Not Reported10001
Region of Enrollment
Region of Enrollment(participants)Regimen 1 RAD1901 5 mgRegimen 2 RAD1901 10 mgRegimen 3 RAD1901 20 mgRegimen 4 PlaceboTotal
United States38342838138
08

Study locations

1 site
  • Women's Health Care Specialists P.C. - Beyer Research
    Kalamazoo, Michigan 49009, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Dec 2016 and a completion of May 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 12, 2016
Start
Dec 2015
Primary completionActual
Dec 12, 2016
CompletionActual
May 1, 2018
Results first posted
Mar 13, 2019
Last update
Mar 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02653417
Lead sponsor
Radius Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 12, 2016
Start date
Dec 2015
Primary completion
Dec 12, 2016
Completion
May 1, 2018
Results posted
Mar 13, 2019
Last update
Mar 13, 2019

Study contacts

Clinical Operations
study director · Radius Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion